Jaakko Patrakka

Jaakko Patrakka serves as an Adjunct Professor of Pathology and Docent at Karolinska Institutet, leading the Renal Glomerulus Biology and Diseases research group within the Department of Laboratory Medicine. His primary focus is deciphering molecular pathways in glomerular diseases—the predominant cause of end-stage renal disease—using transgenic models and single-cell technologies to advance diagnostics and therapeutics.

Dr. Patrakka's research program centers on glomerular biology and disease mechanisms, with emphasis on podocyte function, glomerular injury pathways, and kidney cell heterogeneity. His group pioneers single-cell RNA sequencing applications to identify novel cell types and molecular targets, bridging basic science with clinical translation for chronic kidney disease.

Analysis of his 15 most recent publications reveals a strategic shift toward multi-omics integration and computational pathology, particularly in leveraging deep learning for morphological analysis. Collaborations with AstraZeneca highlight his commitment to drug discovery, while single-cell studies consistently uncover species-specific and disease-stage-specific molecular signatures.

No individual scientific awards, fellowships, or medals are explicitly listed in Dr. Patrakka's public profile.

Dr. Patrakka directs a multidisciplinary team comprising research specialists and postdoctoral fellows, fostering innovation in kidney research. His group's industry partnership with AstraZeneca accelerates therapeutic development, and his work has attracted significant funding, including a 2025 Swedish Kidney Foundation award of SEK 3.4 million for Karolinska Institutet's kidney research initiatives.

The Renal Glomerulus Biology and Diseases laboratory employs cutting-edge methodologies including CRISPR/Cas9 in zebrafish, transgenic mouse modeling, spatial transcriptomics, and super-resolution imaging. Current projects focus on NPR3 receptor signaling in glomerular disease, Klotho-mediated cytoprotection, and dendrin's role in IgA nephropathy, positioning the group at the forefront of nephrology research.